SCHEMBL4138948

SCHEMBL4138948

COC(=O)c1ccc(CN2CCC3(CC2)CCN(C2CCC2)CC3)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.54
CHKA P35790 1/20 0.52
HRH3 Q9Y5N1 2/20 0.51
KMT2A Q03164 3/20 0.51
MEN1 O00255 2/20 0.51
MAPT P10636 1/20 0.51
ATM Q13315 1/20 0.51
CXCR3 P49682 1/20 0.50
POLB P06746 1/20 0.50
L3MBTL1 Q9Y468 2/20 0.49
MBTD1 Q05BQ5 1/20 0.49
L3MBTL3 Q96JM7 1/20 0.49
KDM1A O60341 1/20 0.48
MAOB P27338 1/20 0.48
LMNA P02545 1/20 0.48
MAPK1 P28482 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
ALDH1A1 P00352 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C19 P33261 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4236471 0.90 KDM1A (0.50) KDM4ECHKAKMT2AMEN1MAPT
SCHEMBL4125514 0.86 HRH3 (0.51) KDM4EHRH3KMT2ACXCR3L3MBTL1
SCHEMBL4286696 0.84 HRH3 (0.54) KDM4EHRH3KMT2AMEN1POLB
SCHEMBL20333157 0.79 MEN1 (0.60) KDM4ECHKAKMT2AMEN1MAPT
SCHEMBL2873979 0.78 CHKA (0.72) KDM4ECHKAHRH3KMT2AMEN1
SCHEMBL20210248 0.78 CHKA (0.77) KDM4ECHKAKMT2AMEN1MAPT
SCHEMBL4143448 0.77 ALDH1A1 (0.59) HRH3KMT2AMEN1MAPK1SMN1; SMN2
SCHEMBL228900 0.77 CHKA (0.71) KDM4ECHKAHRH3KMT2AMEN1
SCHEMBL1335735 0.77 CHKA (0.71) KDM4ECHKAHRH3KMT2AMEN1
Hydrochloric Acid SCHEMBL3882134 0.77 CHKA (0.71) KDM4ECHKAHRH3KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2021004-A2 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION (US) 2009-02-11 EP claimed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US claimed
WO-2007133561-A2 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION (US) 2007-11-22 WO claimed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US disclosed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US disclosed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US disclosed
WO-2007133561-A2 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION (US) 2007-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES HRH3, HRH4, HRH1 KDM4E 1025/4885CHKA 1038/4885HRH3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.